ArtiQ joins forces with Clario in strategic acquisition deal to transform respiratory solutions

Only five years after its founding, ArtiQ is being acquired to accelerate its impact on healthcare and clinical trials markets. ArtiQ was founded in 2019 as a KU Leuven and BREATHE research group spin-off by Marko Topalovic, Wim Janssens, Bart Swaelens and Marc Decramer. All founders with strong backgrounds and commitment to the respiratory and healthcare world.

This acquisition comes at the moment of ArtiQ's evident impact on the respiratory market and will further accelerate growth across the world and across all pharmaceutical sponsors who are developing respiratory treatments. Additionally, ArtiQ’s healthcare AI product line will continue to advance the early and accurate detection of respiratory diseases. With this acquisition, Clario's respiratory devices will seamlessly integrate with ArtiQ's advanced AI models, empowering clinicians with instant feedback on test quality. This integration promises to expedite the delivery of faster, more reliable data for sponsors while enhancing the overall patient experience.

In addition to continuing to lead ArtiQ, Marko Topalovic CEO at ArtiQ, will step in to lead Clario’s overall AI strategy across the organization. Of the acquisition, he said: “Joining forces with Clario is a pivotal moment for ArtiQ. Our technology’s integration into Clario’s portfolio not only enhances the quality and efficiency of spirometry data analysis but also marks a sizable step toward minimizing the patient burden and improving trial outcomes. He added: “This acquisition is a testament to the hard work and dedication of ArtiQ's amazing team. The team's commitment has been the driving force behind all our achievements, and with such a strong team, ArtiQ will continue to thrive and flourish in the future.”

“We're thrilled to welcome ArtiQ into our organization,” said Chris Fikry, CEO at Clario. “Since 2018, Clario has been a pioneer in applying artificial intelligence with a human touch to transform clinical trial endpoint analysis. This move significantly advances AI within our respiratory portfolio. With ArtiQ’s technology, we are expanding our ability to rapidly scale AI for overreading while ensuring data quality and streamlining the clinical trial process for patients around the world.”

The success of ArtiQ also highlights the trust and support given on this remarkable journey by KU Leuven, University Hospitals Leuven, and the early investors Gemma Frisius Fund and KBC Focus Fund.